It is well known that anticancer agents can generate ROS to mainly accumulate ROS in the mitochondria of cancer cells for activating apoptotic signaling pathways including PI3K/Akt, MAPKs, NF-κB, nuclear factor (erythroidderived2)-like 2 (Nrf2)/Kelch like-ECH-associated protein 1 (Keap1), and the tumor suppressor p53 and finally induce cancer cell damage and death (Halliwell, 2011; Jeong and Joo, 2016; Redza-Dutordoir and Averill-Bates, 2016). Here, TP53 is linked to cancer.